Changes in bone mineral content following hormone treatment for endometriosis
article
OA: closed
CC0
⤵ 9 in-corpus citations
AI-generated summary
Buserelin treatment for endometriosis significantly decreased lumbar vertebral bone mineral content, while danazol treatment resulted in a slight gain despite estrogen reduction.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The effects of danazol and buserelin on the bone mineral content (BMC) of 19 Japanese women with endometriosis were studied. Subjects received 24-week courses of oral danazol (400 mg/day) or intranasal buserelin (900 micrograms/day). Trabecular BMC of the 3rd lumbar vertebra (L3) was monitored by computerized tomography scans pretreatment, at the end of treatment and 6 months post-treatment. In the buserelin group there was a significant decrease in BMC (10-25.4%, P < 0.01) which was not fully reversed 6 months after therapy, and increased parameters of bone resorption. In the danazol group, there was a slight gain in BMC despite a decrease in serum estrogen. Danazol and buserelin have similar success in the treatment of endometriosis, but the decrease in BMC at L3 suggests that cumulative bone loss may follow repeated buserelin therapy.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (16)
- Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol via openalex
- Danazol. A synthetic steroid with diverse biologic effects. via openalex
- Danazol Suppresses the Production of Interleukin‐1β and Tumor Necrosis Factor by Human Monocytes via openalex
- Endometriosis : contemporary concepts in clinical management via openalex
- Hormone treatment of endometriosis: The estrogenthreshold hypothesis via openalex
- W2287757320 via openalex
- W2337197041 via openalex
- W2413828242 via openalex
- W2416855537 via openalex
- W2473838833 via openalex
- W268898785 via openalex
- W4252543199 via openalex
- W2031689741 via openalex
- W2082351657 via openalex
- W2112810634 via openalex
- W2129449855 via openalex
Cited by (9)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- TRATAMIENTO DE LA ENDOMETRIOSIS I Y II: REVISIÓN DE LA LITERATURA A review of the literature concerning treating endometriosis I and II 2008
- Tratamiento de la endometriosis I y II. Revisión de la literatura 2008
- Tratamiento médico de la endometriosis (excluyendo la adenomiosis) 2006
- Traitement médicamenteux de l'endométriose (adénomyose exclue) 2005
- Traitement médicamenteux de l'endométriose (adénomyose exclue) 2005
- Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density 2003
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 1999
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 1999
Source provenance
- europepmc
- last seen: 2026-06-16T06:07:01.518242+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:11:13.665691+00:00
License: CC0
· commercial use OK